News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Neumann Mark
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Sold 55,300 shares
@ $58.79, valued at
$3.3M
Exercised 55,300 options to buy
@ $18.59, valued at
$1M
|
|
| 08/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/13/2023 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 16,708 shares
@ $0
Sold 6,750 shares
@ $43.5, valued at
$293.6k
Sold 1,800 shares
@ $42.74, valued at
$76.9k
Sold 3,335 shares
@ $45.1, valued at
$150.4k
Sold 423 shares
@ $44.05, valued at
$18.6k
Exercised 7,344 restricted stock units
@ $0 |
|
| 03/08/2023 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 39,398 restricted stock units
@ $0 |
|
| 03/03/2023 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Sold 7,241 shares
@ $50.01, valued at
$362.1k
|
|
| 02/27/2023 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Sold 4,046 shares
@ $47.12, valued at
$190.6k
Exercised 7,906 restricted stock units
@ $0 |
|
| 02/22/2023 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Sold 3,140 shares
@ $46.61, valued at
$146.4k
Sold 123 shares
@ $47.32, valued at
$5.8k
Sold 635 shares
@ $48.93, valued at
$31.1k
Exercised 11,139 restricted stock units
@ $0 |
|
| 04/08/2022 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Sold 17,476 shares
@ $63.55, valued at
$1.1M
Sold 53,987 shares
@ $64.42, valued at
$3.5M
Sold 14,885 shares
@ $65.14, valued at
$969.6k
Exercised 86,348 options to buy
@ $12.73, valued at
$1.1M
|
|
| 03/14/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/25/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/23/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/11/2022 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Sold 2,761 shares
@ $41.74, valued at
$115.2k
Sold 13,935 shares
@ $40.8, valued at
$568.5k
Sold 4,252 shares
@ $40.09, valued at
$170.5k
Exercised 20,948 restricted stock units
@ $0 |
|
| 10/19/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/25/2021 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 18,714 options to buy
@ $36.89, valued at
$690.4k
Granted 23,719 restricted stock units
@ $0 |
|
| 02/22/2021 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Sold 4,584 shares
@ $39.26, valued at
$180k
Sold 600 shares
@ $38.9, valued at
$23.3k
Exercised 11,139 restricted stock units
@ $0 |
|
| 01/12/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/16/2020 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Sold 6,792 shares
@ $26.8, valued at
$182k
Exercised 13,448 restricted stock units
@ $0 |
|
| 02/20/2020 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 26,754 options to buy
@ $23.94, valued at
$640.5k
Granted 33,417 restricted stock units
@ $0 |
|
| 01/10/2020 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Disposed of 6,157 shares
@ $26.34, valued at
$162.2k
Exercised 20,947 restricted stock units
@ $0 |
|
| 10/17/2019 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Sold 6,774 shares
@ $8.25, valued at
$55.9k
Exercised 13,448 restricted stock units
@ $0 |
|
| 01/10/2019 |
4
| Neumann Mark (EVP, Chief Commercial Officer) has filed a Form 4 on Intra-Cellular Therapies, Inc.|
Txns:
| Granted 86,348 options to buy
@ $12.73, valued at
$1.1M
Granted 62,843 restricted stock units
@ $0 |
|
| 10/17/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/17/2018 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
|
|